产业与学术界之间的透明合作可满足未满足的患者需求并促进生殖公共卫生
本文分析了制药与器械产业对生殖医学诊断和治疗的贡献,指出产业与学术界合作常被负面看待,但当前更需要双方合作以加速创新应用。文章介绍了欧洲制药工业协会联合会(EFPIA)的合规与披露政策如何实现合作透明化,并讨论了学术界的科学偏倚风险及通过国际共识、透明利益声明和主动共同作者身份来减少偏倚的可能方案。
要点
- 产业与学术合作可基于互补知识加速诊断、药物和器械的创新与患者可及。
- EFPIA披露政策要求会员公司披露向医疗专业人员和机构转移的价值。
- 科学偏倚在学术界同样存在,国际共识和透明利益声明有助于减少偏倚。
核心结论
- 产业与学术界的透明合作有助于缩短创新与应用的时间线,使患者和社会更快获得更好的诊断、药物和器械。
- 中立性不存在,医疗专业人员、组织和制药产业内部及之间存在不同信念和偏倚,挑战在于始终透明并采取知情、平衡和符合伦理的行为。
研究设计与样本
- 本文为观点性文章,讨论产业与学术界在生殖医学中的合作、透明化政策及科学偏倚问题,未报告系统检索范围或样本量。
主要发现
- EFPIA发布的合规与披露政策使欧洲制药产业与医生之间的合作透明化成为可能,该联合会代表在欧洲运营的主要制药公司,成员包括部分但不包括全部活跃于不孕症和女性健康的公司。
- 根据EFPIA披露行为准则,公司需披露价值转移,包括金额、活动类型以及接收方医疗专业人员和组织的名称。
- EFPIA会员公司已根据良好临床实践和其他法规,在临床研究的设计、统计分析、报告、发表和传播中实施非常严格的内部质量控制流程和程序,并定期接受美国食品药品监督管理局(FDA)或欧洲药品管理局(EMA)等主管机构的检查。
- 科学偏倚的风险不仅存在于制药产业,也存在于学术界;当学者相信某一假设时,可能通过强调支持其案例的论据并驳斥、拒绝、反对或忽视挑战其假设的论据来构建案例。
- 减少这种偏倚的可能解决方案是就研究设计、数据收集、统计分析和结果报告达成国际共识,尤其是在个性化生殖医学领域,例如证明使用生物标志物的个性化卵巢刺激的优效性或非劣效性。
关键数值与推荐
- 根据EFPIA披露行为准则,公司需披露价值转移,包括金额、活动类型以及接收方医疗专业人员和组织的名称。
- 利益声明应在科学摘要和出版物中透明、完整地报告,幽灵作者身份应由产业专家基于现行ICMJE标准要求时的主动明确共同作者身份取代。
- 评审者不应认为仅由产业作者或产业与学术界混合共同作者撰写的出版物比仅由学术团体撰写的论文更容易存在偏倚;工作的科学质量应是接受论文或摘要的唯一相关标准,无论工作在哪里完成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The pharmaceutical and device industry has greatly contributed to diagnostic and therapeutic approaches in reproductive medicine in a very highly regulated environment, ensuring that development and manufacturing follow the highest standards. In spite of these achievements, collaboration between industry and physicians/academia is often presented in a negative context. However, today more than ever, partnership between industry and academia is needed to shorten the timeline between innovation and application, and to achieve faster access to better diagnostics, drugs and devices for the benefit of patients and society, based on complementary knowledge, skills and expertise. Such partnerships can include joined preclinical/clinical and post-marketing research and development, joint intellectual property, and joint revenue. In Europe, the transparency of this collaboration between pharmaceutical industry and medical doctors has been made possible by the Compliance and Disclosure Policy published by the European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents the major pharmaceutical companies operating in Europe, and includes as members some but not all companies active in infertility and women's health. Under the EFPIA Disclosure Code of conduct, companies need to disclose transfers of value including amounts, activity type and the names of the recipient Health Care Professionals and Organizations. EFPIA member companies have also implemented very strict internal quality control processes and procedures in the design, statistical analysis, reporting, publication and communication of clinical research, according to Good Clinical Practice and other regulations, and are regularly inspected by competent authorities such as the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) for all trials used in marketing authorization applications. The risk of scientific bias exists not only in the pharmaceutical industry but also in the academic world. When academics believe in a hypothesis, they may build their case by emphasizing the arguments supporting their case, and either refute, refuse, oppose or ignore arguments that challenge their assumptions. A possible solution to reduce this bias is international consensus on study design, data collection, statistical analysis and reporting of outcomes, especially in the area of personalized reproductive medicine, e.g. to demonstrate superiority or non-inferiority of personalized ovarian stimulation using biomarkers. Equally important is that declarations of interest are reported transparently and completely in scientific abstracts and publications, and that ghost authorship is replaced by proactive and clear co-authorship for experts from industry where such co-authorship is required based on the prevailing ICMJE criteria. In that context, however, reviewers should stop believing that publications by industry authors only, or by mixed groups of co-authors from industry and academia, are more prone to bias than papers from academic groups only. Instead, the scientific quality of the work should be the only relevant criterion for acceptance of papers or abstracts, regardless of the environment where the work was done. In the end, neutrality does not exist and different beliefs and biases exist within and between healthcare professionals and organizations and pharmaceutical industries. The challenge is to be transparent about this reality at all times, and to behave in an informed, balanced and ethical way as medical and scientific experts, taking into account compliance and legal regulations of both industry and academic employers, in the best interest of patients and society.
引用
- D'Hooghe T. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health. Hum Reprod. 2017. PMID: 28854594. doi:10.1093/humrep/dex230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。